Clinical trials recruiting for Recurrent Lung Non-Small Cell Carcinoma
12
Recruiting trials
51
US states with sites
5
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Ohio | 7 |
| Washington | 7 |
| Minnesota | 6 |
| California | 5 |
| District of Columbia | 5 |
| Florida | 5 |
| Massachusetts | 5 |
| Michigan | 5 |
| Missouri | 5 |
| New York | 5 |
| North Carolina | 5 |
| Pennsylvania | 5 |
Top cities
Seattle, Washington 7Columbus, Ohio 6St Louis, Missouri 5Washington D.C., District of Columbia 5Anaconda, Montana 4Baltimore, Maryland 4Billings, Montana 4Bloomington, Illinois 4Boise, Idaho 4Bozeman, Montana 4
Self-screener
Recruiting trials
- Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
- MOv19-BBz CAR T Cells in FRa+ Cancers
- PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
- PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
- Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
- Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Related conditions
Trials recruiting for Recurrent Lung Non-Small Cell Carcinoma often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Stage IV Lung Cancer AJCC v8 45Metastatic Lung Non-Small Cell Carcinoma 20Stage III Lung Cancer AJCC v8 22Metastatic Malignant Solid Neoplasm 21Breast cancer 2239Advanced Lung Non-Small Cell Carcinoma 11Unresectable Lung Non-Small Cell Carcinoma 5Unresectable Cutaneous Melanoma 3Thyroid Carcinoma 3
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Recurrent Lung Non-Small Cell Carcinoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.